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Abstract 
The hallmark features of atherosclerosis include accumulation of low-density lipoprotein 
(LDL) carrying cholesterol in the vessel wall, formation of lipid laden foam cells and the 
creation of a pro-inflammatory microenvironment. To date, no effective treatments are 
clinically available for increasing cholesterol efflux from vascular macrophages and inducing 
reverse cholesterol transport. In a recent article in Clinical Science, Zhang and colleagues 
identify the extracellular matrix protein mindin/spondin 2 as a positive regulator of 
atherosclerosis. Genetic knockout of mindin in apolipoprotein-E (apoE)-/- mice attenuated 
atherosclerosis, foam cell formation and inflammation within the vessel wall. Conversely, 
selective overexpression of mindin in macrophages in apoE-/- mice was sufficient to promote 
a greater severity of atherosclerosis. Interestingly, foam cell formation was closely 
associated with expression of cholesterol transporters (ABCA1 and ACBG1) that facilitate 
cholesterol efflux. Liver X receptor-β (LXR-β) is a key modulator of cholesterol transporter 
expression and formed direct interactions with mindin. Furthermore, the protective effects of 
mindin deficiency on foam cell formation were blocked by inhibition of LXR-β. This article 
highlights a novel role for mindin in modulating foam cell formation and atherosclerosis 
development in mice through direct regulation of LXR-β. Thus far, direct targeting of LXR-β 
via pharmacological agonists has proven problematic due to the lack of subtype selective 
inhibitors and associated adverse effects. Indirect targeting of LXR-β, therefore, via mindin 
inhibition offers a new therapeutic strategy for increasing LXR-β induced cholesterol efflux, 
reducing foam cell formation and preventing or treating atherosclerosis. 
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Atherosclerosis is a disease associated with accumulation of cholesterol within 
macrophages, resulting in the formation of macrophage foam cells, which form the key 
innate component of the chronic non-resolving inflammatory response that characterises the 
evolving atherosclerotic plaque [1]. 
Disruption of normal cholesterol homeostasis resulting in an excess of cholesterol inside 
macrophages within the vessel wall promotes the formation of foam cells [2]. Foam cells 
display a pro-inflammatory phenotype and release local inflammatory mediators such as 
interleukin (IL)-1β, inducible nitric oxide synthase (iNOS) and IL-6 that facilitates additional 
leukocyte recruitment and contributes to the pro-inflammatory status of a growing atheroma. 
Accumulation of intracellular cholesterol depends on the balance between cholesterol influx 
and efflux. Cholesterol efflux from macrophages relies on the ATP-binding cassette 
transporters, ABCA1 and ABCG1 which transfer cholesterol to high-density lipoprotein (HDL) 
[3, 4]. HDL carries excess cholesterol to the liver and eventually intestine for excretion, thus 
completing the process of reverse cholesterol transport (RCT). Therefore, macrophage lipid 
metabolism and foam cell formation represent an important target for therapeutic research in 
atherosclerosis. 
To date, strategies aimed at modulating RCT such as cholesteryl ester transfer protein 
inhibitors have performed poorly in clinical trials. Another therapeutic target that has had a 
troubled development path is apolipoprotein A-1 Milano, a naturally occurring mutant form of 
apolipoprotein A-1 that is expressed in heterozygous form by a small population of people 
from Limone sul Garda in Italy, who have remarkably low levels of cardiovascular disease 
despite marked reductions in HDL [5]. Carriers of this particular mutant form display 
increased cholesterol efflux which may, in part, explain their reduced cardiovascular risk [6]. 
However, with the discontinuation of MDCO-216 (synthetic recombinant apolipoprotein A-1 
Milano) in 2016 (http://www.themedicinescompany.com/investors/news/medicines-company-
discontinues-development-mdco-216-its-investigational-cholesterol), alternative approaches 
are required if RCT is to become a viable therapeutic means by which to normalise 
cholesterol homeostasis in cardiovascular patients. 
Each stage of the RCT process is mediated by Liver X receptors (LXRs) through their 
modulation of cholesterol transporters. LXRs are members of the nuclear receptor family of 
transcription factors and are composed of two isoforms: LXR-α and LXR-β. Both isoforms, to 
some degree, have overlapping tissue distribution, with LXR-α the dominant isoform in the 
liver and other metabolic organs but with LXR-β displaying the more widespread distribution. 
LXRs can act as cholesterol sensors with physiological concentrations of modified 
cholesterol such as 22(R)-, 24(S)- and 27-hydroxycholesterol acting as activators of LXRs 
with subsequent transcription of genes that carry an LXR response element (LXRE) in their 
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promoter region. In several cell types including macrophages, ABCA1 and ABCG1 carry 
LXREs [7, 8]. When intracellular cholesterol concentrations rise, LXR ligands can induce 
upregulation of ABCA1 and ABCG1, thus promoting cholesterol efflux and thereby acting to 
preserve cholesterol homeostasis in macrophages [9, 10]. LXR ligands are atheroprotective 
in animal models and macrophages are thought to be the primary target cell through which 
LXR ligands act [10] by initiating the transfer of cholesterol to HDL. 
A direct correlation between the extent of cholesterol efflux from macrophages and 
cardiovascular disease risk has been established in humans with subjects displaying the 
highest level of macrophage cholesterol efflux showing a reduction in adverse 
cardiovascular events compared with the cohort with the lowest levels [11]. Therefore, as 
key mediators for promoting cholesterol removal from macrophages and the vessel wall, 
LXR ligands have been the target of therapeutic interest. A limiting factor in the search for 
therapeutic LXR ligands is their ability to induce hyperlipidaemia and hypertriglyceridemia, 
contraindicating their use in cardiovascular disease patients. Studies in animal models of 
atherosclerosis have identified selective activation of LXR-β as being protective in 
atherosclerosis with the hyperlipidaemic effects being ascribed to LXR-α; however, LXR-β 
selective drugs have thus far failed to translate from animal models to humans [12]. 
In the study by Zhang and colleagues [13], recently published in Clinical Science, a potential 
new upstream modulator of LXR-β is described. The authors investigate the extracellular 
matrix protein, mindin (spondin 2), a member of the mindin/F-spondin family of extracellular 
matrix proteins. Mindin has regulatory roles in diseases including cancer, diabetes and 
cardiometabolic disorders. Evidence also exists for an immunoregulatory role [14] but a 
specific role in modulating atherosclerosis has not been investigated until now. 
Zhang and colleagues describe a role for mindin as a positive regulator of atherosclerosis. 
Using apolipoprotein-E (apoE)-/- mice deficient in mindin in addition to apoE-/- mice that 
display overexpression of mindin exclusively in macrophages, the authors employed a series 
of experiments to investigate the effect of mindin on plaque burden and foam cell formation 
before investigating the mechanisms underlying these phenotypic changes. Following 
initiation of high-fat diet (HFD) feeding, apoE-/- mice displayed increased levels of mindin in 
serum from as early as 6 weeks on HFD, with serum levels steadily rising to a peak at 28 
weeks HFD (the end point of the study). Crossing mindin-/- mice with apoE-/- mice yielding 
mindin-/-apoE-/- double knockouts resulted in a 60% decrease in plaque burden following 28 
weeks HFD compared with apoE-/- control mice and the remaining plaques displayed a more 
stable plaque phenotype with reduced lipid concentration and greater vascular smooth 
muscle cell content. The latter data is in line with previous results demonstrating that mindin 
deletion increased smooth muscle cell proliferation in a wire-injury mouse model [15]. 
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Importantly, these results were not dependent on circulating lipid levels, which were 
equivalent between the two groups. Immunofluorescence staining of plaques revealed 
localisation of mindin was mostly confined to lesional macrophages with mindin deficient 
arteries displaying reductions in several key inflammatory mediators: IL-6, iNOS and the 
chemokine (C-C motif) ligand 2, also known as monocyte chemoattractant protein 1. To 
ascertain whether the athero-protective effect of mindin deficiency is dependent on its 
function within the aortic wall or in hematopoietic cells, four different groups of chimeras 
were generated by injecting bone marrow (BM) cells from apoE-/- or mindin-/-apoE-/- donors 
into apoE-/- or mindin-/-apoE-/- recipient mice subjected to whole-body irradiation. Results 
clearly indicated mindin deficiency is more important in BM-derived hematopoietic cells than 
it is in vascular wall cells. Consistent with this observation was the reduced foam cell 
formation observed in BM derived macrophages (BMDMs) isolated from mindin-/-apoE-/- mice 
treated with ox-LDL. This result prompted the authors to consider mindin may be having a 
regulatory role in cholesterol trafficking. Mindin deficiency was associated with enhanced 
expression of ABCA1 and ABCG1 but not receptors or enzymes associated with cholesterol 
uptake or processing, confirming mindin was specifically influencing the efflux of cholesterol 
from macrophages. Utilizing apoE-/- mice with macrophage-specific overexpression of mindin 
(Lyz2-mindin-TG) resulted in a worsening of atherosclerosis, increased lipid accumulation 
and increased macrophage derived inflammatory mediators. A similar increase in foam cell 
formation was observed in BMDMs from Lyz2-mindin-TG in vitro. Given the importance that 
LXR-β has in regulating ABCA1 and ABCG1 expression, the authors investigated a 
mechanistic link between mindin and LXR-β on cholesterol efflux. LXR-β was increased in 
the aorta and ox-LDL treated BMDMs derived from mindin-/-apoE-/- mice with co-
immunoprecipitation confirming direct interactions between mindin and LXR-β. Finally, to 
establish a direst mechanistic link between mindin and LXR-β, foam cell formation and 
ABCA1 and ABCG1 expression in BMDMs derived from apoE-/- and mindin-/-apoE-/- mice 
were assessed following gene silencing of LXR-β. The inhibition of foam cell formation 
generated by loss of mindin was reversed by LXR-β inhibition with comparable results 
observed for ABCA1 and ABCG1 expression. 
Considering the important role LXR-β has in modulating cholesterol efflux, a word of caution 
is warranted regarding the lack of data on LXR-α which is also expressed in macrophages 
with ABCA1 also being a direct target of LXR-α. Indeed, there is some controversy as to 
which LXR subtype has the most relevance when it comes to modulating atherosclerosis in 
mouse models [16]. Due to the high homology between the two LXR isotypes (only one 
amino acid difference in the ligand binding site), subtype specific ligands are challenging to 
create and those LXR-β subtype selective ligands that have been tested in animals and 
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humans have been associated with increased lipid levels [12]. Nevertheless, LXR-β 
activation remains an attractive therapeutic option, particularly if macrophages are the 
primary cell type targeted. The relative scarcity of LXR-β in the liver compared with LXR-α 
may reduce the risk of hepatic steatosis, a side effect of non-selective LXR ligands in animal 
models [12]. Future studies will be required to ascertain if mindin inhibition has a modulating 
influence on LXR-α and the relevance, if any, this effect has on the pathology and potential 
adverse effects. Lipid metabolism is markedly different in rodents than in humans and while 
the lack of increase in circulating lipids noted in mindin-/-apoE-/- mice is encouraging, 
extrapolating the effects of LXR activation on lipid metabolism from animal models to 
humans has previously proved unreliable. For example, BMS-852927, an LXR-β selective 
partial agonist that increased RCT in cynomolgus monkeys was associated with 
hyperlipidaemia in humans, effects not observed in the primate model, despite similar 
efficacy in inducing RCT [12]. It is very possible such effects could be avoided by specific 
targeting of macrophage LXR-β thus avoiding adverse effects on hepatic liver metabolism. 
In summary, the data published by Zhang and colleagues reveal a new role for mindin as a 
pro-atherogenic factor. This role is due to attenuation of foam cell formation and promotion 
of cholesterol efflux following mindin deficiency. That the effects of mindin ablation on 
ABCA1 and ABCG1 expression and foam cell formation could be reversed by inhibition of 
LXR-β suggests mindin directly inhibits LXR-β in an atherosclerotic mouse model thus 
reducing cholesterol transporters and cholesterol efflux. Considering the difficulties in 
designing high potency specific LXR-β ligands and the adverse events associated with 
pharmacological LXR agonists to date, this study offers a rationale for designing mindin 
inhibitors as a novel mechanism for enhancing macrophage LXR-β activation and promoting 
cholesterol efflux as a therapeutic strategy in cardiovascular disease. 
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